Search PubMed⌕ Search

Biomedical subjects

M Otsuki

Publications and source records attributed to M Otsuki.

At least 181 records · Page 10Linked to original sources
PubMed1994

[Transcortical sensory aphasia following a left frontal lesion--case report].

We report a patient with transcortical sensory aphasia (TCSA) following a left frontal lesion. The patient was a 63-year-old right handed Buddhist priest admitted to our hospital with a complaint of word-finding difficulty. Neurological examination failed to reveal any abnormal findings except aphasia. The patients spontaneous speech was fluent, not agrammatic, and free of phonemic paraphasia but he sometimes exhibited semantic paraphasia. His ability to repeat sentences was excellent, but he had severe difficulty in word-finding, auditory comprehension and writing. He read aloud correctly, but his reading comprehension of kana (phonograms) was poor in contrast to excellent reading comprehension of kanji (morphonograms). His clinical picture was characterized by poor comprehension but excellent repetition, and a diagnosis of TCSA was made. CT and MRI revealed an infarction involving the pars opercularis and pars triangularis in the inferior frontal gyrus and the anterior portion of the lower prefrontal gyrus and the middle frontal gyrus. Regional cerebral blood flow was measured by single photon emission CT and was found to be decreased in the same region as indicated on CT and MRI. The clinical picture in this patient was comparable to that of TCSA due to a posterior parieto-occipital lesion, but the rapid improvement (within 1 to 2 months) of this patient was characteristic. Auditory comprehension, kana (phonograms) reading comprehension, and word recall, which were severely impaired in this patient, all demand interaction between phonological processes and semantic processes. Thus we conclude that this patient had impairment of the phonological-semantic interaction process.

Aphasia, Wernicke↗
PubMed1993

Effect of islet hormones on secretin-stimulated exocrine secretion in isolated perfused rat pancreas.

To clarify the effect of islet hormones on pancreatic ductular cell function, we measured the exocrine secretion elicited by 10 pM secretin in the presence or absence of islet hormones using an isolated perfused rat pancreas model. Insulin significantly increased secretin-stimulated pancreatic juice secretion, but not protein secretion. The potentiating effect of insulin on pancreatic juice secretion was concentration-dependent, and the maximal effect was observed with 1 microM insulin. Ouabain, a specific Na+,K(+)-ATPase inhibitor, caused concentration-dependent inhibition of the potentiating effect of insulin without affecting secretin action. Glucagon (100 nM) significantly inhibited secretin-stimulated pancreatic juice secretion and also tended to inhibit protein secretion. A somatostatin analog, SMS 201-995 (10 nM) significantly inhibited both the pancreatic juice and protein secretion stimulated by secretin. The inhibitory effect of SMS 201-995 was concentration-dependent and was maximal at 1-10 nM. These results demonstrate that insulin potentiates the secretory response to secretin, at least partly by increasing Na+,K(+)-ATPase activity, whereas glucagon and somatostatin inhibit this response. Thus, pancreatic islet hormones regulate the secretory function of pancreatic ductular and centroacinar cells.

Animals↗
PubMed1993

Role of endogenous bile on basal and postprandial CCK release in humans.

The role of intraduodenal bile in regulation of plasma cholecystokinin (CCK) levels were investigated in patients with obstructive jaundice under external bile diversion and under physiological bile flow into the duodenum by internal bile drainage. Basal plasma CCK levels determined by a specific and sensitive bioassay in patients under external bile drainage (2.2 +/- 0.2 pmol/liter; mean +/- SE) were significantly higher than those in control subjects (1.0 +/- 0.3 pmol/liter). In control subjects, the peak CCK response (6.2 +/- 0.7 pmol/liter) to a test meal was seen at 45 min, whereas that in patients under external bile drainage, it was seen at 20 min after a test meal (17.6 +/- 3.2 pmol/liter; P < 0.01 vs controls). After peak response, plasma CCK levels in controls gradually decreased, but remained significantly elevated during a 3-hr observation period. In patients under bile diversion, the test meal caused a prompt plasma CCK peak, with a transient fall followed by a continuous rise until 180 min postprandially. In six patients, external bile diversion was changed to internal biliary drainage with a stent tube within two weeks to maintain physiological bile flow into the duodenum. Internal bile drainage normalized basal (0.9 +/- 0.2 pmol/liter) as well as meal-stimulated CCK release (peak value: 5.0 +/- 0.8 pmol/liter). These results demonstrate that endogenous bile exerts tonic inhibition on basal and postprandial plasma CCK levels in humans.

Adenoma, Bile Duct↗
PubMed1993

Duration and potency of anticholecystokinin action of subcutaneous and oral loxiglumide on cerulein-stimulated pancreatic exocrine secretion.

The duration and the potency of the antiCCK activities of loxiglumide given by sc and oral routes were examined in rats. Pancreatic juice flow and protein output in response to an iv bolus injection of cerulein (100 ng/kg body wt) were measured at specified time intervals from 1-12 h after loxiglumide administration. Subcutaneous loxiglumide (10 g/kg body wt) effectively suppressed cerulein-stimulated protein output for 4 h and pancreatic juice volume for 6 h, when total outputs during a 60-min period after cerulein stimulation were compared with the control value without loxiglumide pretreatment. Oral dose of loxiglumide exerted longer-term anti-CCK activity (protein output: 6 h, pancreatic juice: 8 h) than the same sc dose. In addition, oral loxiglumide showed more potent suppression of protein output than the same sc dose at the corresponding time interval. Higher oral dose of loxiglumide (50 mg/kg body wt) caused longer inhibition on both protein (8 h) and pancreatic juice secretion (12 h). These results suggest that the half-life of loxiglumide given by oral route is longer than that by sc route or that the bioavailability of oral loxiglumide is higher than that of sc dose. The present study demonstrates that loxiglumide, given either by sc or by oral route, has long duration of action in antagonizing responses to exogenously administered cerulein.

Administration, Oral↗
PubMed1993

Characterization of a new diphenylpyrazolidinone cholecystokinin antagonist in vitro isolated rat pancreatic acini.

The effects of a newly developed diphenylpyrazolidinone cholecystokinin (CCK) antagonist LY219,057 were examined in the isolated rat pancreatic acini and compared with those of devazepide (previously designated L364,718 or MK-329). LY219,057 caused a concentration-dependent inhibition of 100 pM CCK octapeptide (CCK-8)-stimulated amylase release, with a half-maximal inhibition (ID50) at 287.5 +/- 28.4 nM and was 200 times less potent than devazepide (ID50 = 1.4 +/- 0.2 nM). The antagonism was competitive in nature because LY219,057 caused a parallel rightward shift of the dose-response curve for CCK-8-stimulated amylase secretion without altering the maximal increase. LY219,057 significantly inhibited amylase release in response to CCK-8 and cerulein but had no effect on amylase release stimulated by other receptor secretagogs or agent bypassing receptors. LY219,057, whether added at the beginning or 20 min after the CCK-8 stimulation, inhibited amylase release. This compound caused a residual inhibition of the action of CCK-8. Acini preincubated with 1.0 microM LY219,057 for 30 min at 37 degrees C were threefold less sensitive to CCK-8 than the acini preincubated without LY219,057. These results indicate that LY219,057 acts as a potent, competitive, and specific CCK receptor antagonist of the action of CCK on the exocrine pancreas.

Amylases↗
PubMed1993

Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop.

Involvement of endogenous cholecystokinin (CCK) in the development of acute pancreatitis induced in rats by closed duodenal loop (CDL) was examined, and the effects of the potent and specific CCK receptor antagonist loxiglumide on this model of acute pancreatitis were evaluated. Plasma CCK bioactivity was markedly elevated 3 and 6 h after onset of acute pancreatitis. A single subcutaneous injection of 50 mg/kg body wt of loxiglumide 30 min before the induction of acute pancreatitis completely eliminated the hypercholecystokinemia. Loxiglumide given 3 h after the induction of acute pancreatitis suppressed plasma CCK bioactivity, which had risen up to 30-fold over basal value (0 h) at 3 h, to nearly the basal level. Loxiglumide pretreatment, in addition, significantly prevented the rise in serum amylase and lipase activity, as well as the increase in ascitic volume. It also ameliorated histological alterations of hemorrhagic and necrotizing pancreatitis. Reduction of plasma CCK bioactivity by loxiglumide after the onset of pancreatitis slowed the rate of progression of pancreatitis. However, pancreatic wet weight and cellular infiltration were not significantly influenced by loxiglumide treatment. These observations suggest that endogenous CCK is not involved in the initiation of acute hemorrhagic and necrotizing pancreatitis induced by CDL, but is involved in the development of pancreatitis in this model.

Acute Disease↗
PubMed1993

Differential effects of proteinase inhibitor camostat on exocrine pancreas in fed and fasted rats.

Effects of an oral dose of the synthetic trypsin inhibitor camostat on pancreatic exocrine function were examined in rats that were either fasted from 12 h before feeding camostat to the end of experiments or fed ad libitum. Camostat (100 mg/kg body wt) caused significant increases in plasma cholecystokinin bioactivity (peak 13.4 +/- 2.0 pM at 30 min for fasted rats vs. 16.6 +/- 1.7 pM at 2 h for fed rats; not significant) and pancreatic exocrine secretion. In fed rats, but not in fasted rats, significant increases in pancreatic exocrine secretion were observed again at 12 h after a single oral dose of camostat (juice flow 10.3 +/- 0.4 microliters/20 min in fasted rats vs. 175.5 +/- 17.8 microliters/20 min in fed rats; P < 0.001), although pancreatic juice flow in fed and fasted control rats was nearly the same. When the pancreata from camostat-pretreated rats were isolated and perfused, the early effects of camostat on pancreatic exocrine secretion were abolished, whereas the late effects (12 h postfeeding) in fed rats were still observed (juice flow 33.7 +/- 3.4 microliters/20 min vs. control 2.8 +/- 0.4 microliters/20 min; P < 0.001). Thus, in addition to humoral and neural factors, persistent functional changes might have occurred in the pancreas of the fed camostat-pretreated rats. These present results indicate that oral camostat induces two different effects, immediate and delayed, on pancreatic exocrine secretory function. Camostat exerts its immediate effects in both fed and fasted rats, whereas delayed effects were induced only in fed rats.

Administration, Oral↗
PubMed1993

[Inhibitory effect of somatostatin analogue, SMS 201-995, on secretin-stimulated exocrine secretion in isolated perfused rat pancreas].

In order to clarify the effect of somatostatin of the ductal secretion of the exocrine pancreas, we measured pancreatic juice and protein secretion stimulated with 10 pM secretin and/or 10 pM cholecystokinin (CCK) in the presence or absence of somatostatin analogue, SMS 201-995 (SMS) utilizing the isolated perfused pancreas of rats. SMS significantly inhibited both pancreatic juice flow and protein output elicited by 10 pM secretin without affecting basal secretion. The inhibitory effect of SMS was dose-dependent and maximal inhibition was observed with 1-10 nM. Half-inhibitory dose of SMS for juice secretion was 140 pM. Because CCK is thought to potentiate secretin action on the ductal system, we examined the effect of SMS on pancreatic secretory response to 10 pM secretin in combination with 10 pM CCK. In the experimental system we used, the amounts of pancreatic juice and protein secreted during a 30-min stimulation with secretin and CCK were additive. SMS inhibited both pancreatic juice and protein secretion to the level comparable with that obtained with either stimulus and SMS. SMS had no effect on CCK-stimulated pancreatic juice secretion but significantly inhibited protein output. The present study demonstrated, therefore, that SMS inhibits ductal secretion in response to physiological concentration of secretin.

Animals↗
PubMed1993

[Plasma cholecystokinin levels in rats with pancreatic insufficiency induced by intra ductal injection of oleic acid].

Plasma cholecystokinin (CCK) levels in rats with pancreatic insufficiency induced by a single injection of 50 microliters oleic acid into the pancreatic duct were determined by a sensitive and specific bioassay using the isolated rat pancreatic acini. Treatment with oleic acid significantly decreased pancreatic wet weight within 7 days, which lasted until the end of observation (56 days). Histologic examination revealed the destruction of acinar cells and the epithelium of intra- and interlobular ducts. Plasma CCK bioactivity was significantly increased from the pre-treatment values of 0.8 +/- 0.1pM to 5.1 +/- 1.4pM at 24h after oleic acid treatment. After this peak, plasma CCK levels gradually decreased. Even after 56 days, however, plasma CCK levels in oleic acid-treated rats were significantly high compared with those in control rats. In the present study, plasma CCK levels in rats with chronic pancreatitis did not correlate with the progress of pancreatic insufficiency.

Animals↗
PubMed1993

[Effect of cholecystokinin and secretin on insulin binding to rat pancreatic acini and pancreatic cancer cell line AR42J cells].

In order to clarify the interaction of hormones which exert various effects on the exocrine pancreas, we investigated the effect of cholecystokinin (CCK) and secretin on subsequent insulin binding to pancreatic acini and cultured AR42J cells derived from azaserine-induced acinar cell carcinoma of the pancreas. CCK at concentrations of 100pM-10nM inhibited subsequent 125I-insulin binding to pancreatic acini. 12-O-tetradecanoylphorbol 13-acetate (TPA) inhibited 125I-insulin binding whereas A23187 had little effect, suggesting that the inhibitory effect of CCK is mediated by protein kinase C. On the other hand, 100pM-10nM secretin had no effect on subsequent 125I-insulin binding to pancreatic acini, although higher concentrations of forskolin and 8 bromoadenosine 3', 5'-cyclic monophosphate inhibited 125I-insulin binding. In addition, secretin exerted no potentiating effect on the inhibitory effect of CCK on 125I-insulin binding to pancreatic acini. Based on these results, we further investigated the effect of CCK and TPA on subsequent 125I-insulin binding to AR42J cells. In this carcinoma cell line, inhibitory effect of CCK and TPA on insulin binding was completely abolished. The present results suggest, therefore, that hormonal interaction may play an important role in the regulation of exocrine pancreatic function including acinar cell growth.

Animals↗
PubMed1992

In vitro and in vivo activities of DQ-2556 and its mode of action.

DQ-2556 is a recently developed cephalosporin with a broad spectrum of antibacterial activity against both gram-positive and gram-negative bacteria. Its in vitro activity was roughly comparable to those of cefuzonam and cefpirome and greater than those of ceftazidime, cefepime, and cefclidin against gram-positive bacteria. Against gram-negative bacteria, DQ-2556 showed almost the same activity as those shown by cefpirome and cefepime. The activity was largely unaffected by culture medium pH or the addition of human serum. The protective effect of DQ-2556 in experimental gram-positive pathogen and Escherichia coli infections in mice was greater than those of ceftazidime, cefuzonam, cefepime, and cefclidin and was similar to that of cefpirome. Against Pseudomonas aeruginosa and Acinetobacter calcoaceticus infections, DQ-2556 was more active than cefuzonam and had activity similar to or less than those of ceftazidime, cefpirome, cefepime, and cefclidin. When cells of E. coli were exposed to various concentrations of DQ-2556, filamentous cells were observed at concentrations of 0.0008 micrograms/ml and greater, spheroplasts started to form at 0.025 micrograms/ml, and subsequent cell lysis was observed. The affinity of DQ-2556 to PBP 3 of E. coli, which participates in septum formation, as suggested by morphological observation, was two times greater than that of ceftazidime. DQ-2556 also had high affinities for PBPs 1B and 1A of E. coli. These results suggest that DQ-2556 is worthy for subsequent clinical trials.

Animals↗
PubMed1992

In vitro antibacterial activity of Q-35, a new fluoroquinolone.

The in vitro activity of Q-35, an 8-methoxy fluoroquinolone, was compared with those of ofloxacin, ciprofloxacin, tosufloxacin, lomefloxacin, and sparfloxacin. The MICs of Q-35 for 90% of strains tested (MIC90s) of Staphylococcus aureus, methicillin-resistant S. aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and Streptococcus pyogenes were 0.2, 6.25, 0.2, 0.39, and 0.39 micrograms/ml, respectively. The activity of Q-35 was 4- to 16-fold greater than those of ofloxacin, ciprofloxacin and lomefloxacin but equal to those of tosufloxacin and sparfloxacin against these organisms. For 82 ciprofloxacin-resistant staphylococci (MIC90 = 100 micrograms/ml), Q-35 was the most active of the new quinolones tested (MIC90 = 6.25 micrograms/ml). The MIC90s of Q-35 against Escherichia coli, Enterobacter aerogenes, and Pseudomonas aeruginosa were 0.2, 0.78, and 12.5 micrograms/ml, respectively, and Q-35 was 2- to 16-fold less active than the other quinolones tested. Q-35 showed potent bactericidal activity and inhibited the supercoiling activity of DNA gyrase of S. aureus, E. coli, and P. aeruginosa.

Anti-Infective Agents↗
PubMed1992

In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin with a broad antibacterial spectrum.

E1077 is a new injectable cephalosporin with a broad spectrum of antibacterial activity against gram-positive and gram-negative bacteria, including staphylococci and Pseudomonas aeruginosa. The in vitro activities of E1077 against clinical isolates of methicillin-susceptible Staphylococcus aureus (MIC of E1077 for 90% of the strains tested [MIC90], 0.78 microgram/ml) and methicillin-resistant S. aureus (MIC90, 50 micrograms/ml) were similar to those of cefpirome and flomoxef. Against Enterococcus faecalis (MIC90, 6.25 micrograms/ml), E1077 was the most active of the drugs tested and four times more active than cefpirome. The MIC90S of E1077 for streptococci, Haemophilus influenzae, and Neisseria gonorrhoeae ranged from 0.05 to 0.78 microgram/ml; E1077 was similar in activity to cefpirome. E1077 inhibited 90% of most species of the family Enterobacteriaceae at concentrations of less than or equal to 1.56 micrograms/ml, with the exception of Serratia marcescens and Proteus vulgaris (12.5 micrograms/ml). The activity of E1077 against P. aeruginosa (MIC90, 6.25 micrograms/ml) was comparable to that of ceftazidime. In vivo activity was evaluated with systemic infections in mice. E1077 showed a protective effect against systemic infections by gram-positive or gram-negative bacteria, as reflected by its in vitro activity. The protective effects of E1077 were higher than those of cefpirome against S. aureus and P. aeruginosa infections and similar to those of cefpirome against other bacterial infections. Morphological studies using differential interference and phase-contrast microscopy showed that low concentrations of E1077 caused swelling of S. aureus and spheroplast and bulge formation in P. aeruginosa. In general, the antibacterial profile of E1077 is similar to that of cefpirome.

Animals↗
PubMed1992

Bactericidal activities of ofloxacin and its optically active isomer (DR-3355) on non-growing cells of Escherichia coli and Pseudomonas aeruginosa.

In this paper the bactericidal activities of ofloxacin and its optically active derivative, DR-3355, against non-growing cells of Escherichia coli and Pseudomonas aeruginosa are described. E. coli and P. aeruginosa were killed rapidly by ofloxacin and DR-3355. After treatment with these quinolones, the resting cells of E. coli and P. aeruginosa became plasmolyzed, with apparent cytoplasmic shrinkage without filamentation. Membrane-bound intracellular vacuoles and disruption of the cell envelope were also observed, resulting in extrusion of the cytoplasmic contents. These results indicate that non-growing cells of E. coli and P. aeruginosa were susceptible to ofloxacin and DR-3355, as were logarithmically growing cells.

Cell Cycle↗
PubMed1992

[The function of red blood cells under open-heart surgery with extracorporeal circulation without donor blood].

In 18 patients scheduled for open-heart surgery with extracorporeal circulation without donor blood, P50, 2, 3-DPG, intracellular sodium and potassium in red blood cells, and erythrocyte deformability were measured for the purpose of investigating the influence of severe hemodilution on oxygen transport and function of red cells. P50 and 2, 3-DPG in red cells showed no significant changes until the end of cardiopulmonary bypass (CPB). At the end of operation, 2, 3-DPG content decreased significantly without a significant change of P50. This is probably due to the rightward shift of oxyhemoglobin dissociation curve as compensation for the hemodilution without donor blood. On the first postoperative day, P50 value and 2,3-DPG content decreased significantly but returned to previous values on the second day. As the result of changes of red cell sodium contents and deformability, erythrocyte morphology recovered soon after the end of CPB, but the membrane function of red cells was restored a few days later. In conclusion, oxygen transport in red cells may be disturbed after open-heart surgery with extracorporeal circulation without donor blood.

Adolescent↗